TY - JOUR
T1 - Multifraction radiotherapy for palliation of painful bone metastases
T2 - 20 Gy versus 30 Gy
AU - Valeriani, Maurizio
AU - Scaringi, Claudia
AU - Blasi, Luciana
AU - Carnevale, Alessia
AU - De Sanctis, Vitaliana
AU - Bonome, Paolo
AU - Bracci, Stefano
AU - Marrone, Gianluca
AU - Minniti, Giuseppe
AU - Enrici, Riccardo Maurizi
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Aims and Background: To compare 2 multifraction radiotherapy schedules in the palliation of painful bone metastases. Methods and Study design: We retrospectively analyzed clinical data of 105 patients with a total of 140 painful bone metastases who were treated with 20 Gy in 5 fractions or 30 Gy in 10 fractions. The primary tumors were breast (30%), lung (28%), and prostate (14%). The main sites of irradiation were spine (n = 79) and sacrum or pelvis (n = 39). Pain was graded by patients according to the pain numeric rating scale just before and 1 month after radiotherapy. Pain progression was defined as an increase .2 on pain scale after an initial response. Results: The overall response rate at 1 month was 88.6%. Overall response rate was 89.6% in the 20-Gy arm and 87.3% in the 30-Gy arm (p = 0.669). The rate of complete response was statistically better in patients treated with 30 Gy (p = 0.019). The mean reduction in pain was 3.2 in the 20-Gy group and 3.6 in the 30-Gy group. Pain progression was 6.5% and 1.6%, respectively. The incidence of acute toxicity was statistically significantly higher in the 30-Gy arm (23.8%) than in the 20-Gy arm (2.6%) (p = 0.001). One pathologic fracture of the irradiated bone was observed in the 30-Gy arm. Two lesions, one in each group, were re-irradiated for pain recurrence. Pain progression was found in 6.5% of the irradiated lesions in the 20-Gy arm and in 1.6% in the 30-Gy arm. Conclusions: In our series, both regimens achieved high rate of pain relief, although the group treated with higher total dose reported better complete response rate. The 30-Gy arm had a significantly higher rate of acute toxicity.
AB - Aims and Background: To compare 2 multifraction radiotherapy schedules in the palliation of painful bone metastases. Methods and Study design: We retrospectively analyzed clinical data of 105 patients with a total of 140 painful bone metastases who were treated with 20 Gy in 5 fractions or 30 Gy in 10 fractions. The primary tumors were breast (30%), lung (28%), and prostate (14%). The main sites of irradiation were spine (n = 79) and sacrum or pelvis (n = 39). Pain was graded by patients according to the pain numeric rating scale just before and 1 month after radiotherapy. Pain progression was defined as an increase .2 on pain scale after an initial response. Results: The overall response rate at 1 month was 88.6%. Overall response rate was 89.6% in the 20-Gy arm and 87.3% in the 30-Gy arm (p = 0.669). The rate of complete response was statistically better in patients treated with 30 Gy (p = 0.019). The mean reduction in pain was 3.2 in the 20-Gy group and 3.6 in the 30-Gy group. Pain progression was 6.5% and 1.6%, respectively. The incidence of acute toxicity was statistically significantly higher in the 30-Gy arm (23.8%) than in the 20-Gy arm (2.6%) (p = 0.001). One pathologic fracture of the irradiated bone was observed in the 30-Gy arm. Two lesions, one in each group, were re-irradiated for pain recurrence. Pain progression was found in 6.5% of the irradiated lesions in the 20-Gy arm and in 1.6% in the 30-Gy arm. Conclusions: In our series, both regimens achieved high rate of pain relief, although the group treated with higher total dose reported better complete response rate. The 30-Gy arm had a significantly higher rate of acute toxicity.
KW - Bone metastases
KW - Multifraction radiotherapy
KW - Palliation
UR - http://www.scopus.com/inward/record.url?scp=84938263272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938263272&partnerID=8YFLogxK
U2 - 10.5301/tj.5000286
DO - 10.5301/tj.5000286
M3 - Article
C2 - 25908049
AN - SCOPUS:84938263272
VL - 101
SP - 318
EP - 322
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 3
ER -